JP2007533298A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007533298A5 JP2007533298A5 JP2006529654A JP2006529654A JP2007533298A5 JP 2007533298 A5 JP2007533298 A5 JP 2007533298A5 JP 2006529654 A JP2006529654 A JP 2006529654A JP 2006529654 A JP2006529654 A JP 2006529654A JP 2007533298 A5 JP2007533298 A5 JP 2007533298A5
- Authority
- JP
- Japan
- Prior art keywords
- derivative
- human
- kda
- polypeptide
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010074108 interleukin-21 Proteins 0.000 claims description 9
- 101001010621 Homo sapiens Interleukin-21 Proteins 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 description 7
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Description
本発明の方法はまた、化学的に修飾されたIL-21組成物を使用する。ここでIL-21ポリペプチドは、ポリマー分子と連結する。具体的IL-21ポリペプチドは、機能的膜貫通ドメインを欠く可溶性ポリペプチド、たとえば成熟(mature)IL-21ポリペプチドである。典型的には、ポリマーは水溶性であり、IL-21結合体は水性環境、例えば生理学的環境において沈殿しない。適切なポリマーの例は、単一の反応基(例えば、アシル化のための活性エステルやアルキル化のためのアルデヒド)をもつように修飾されたポリマーである。ポリマーの重合度は調節することができる。反応性アルデヒドの例には、ポリエチレングリコールプロピオンアルデヒド、またはモノ-(C1-C10)アルコキシ、またはそのアリールオキシ誘導体がある(例えばHarris, et al., 米国特許番号5,252,714号を参照)。ポリマーの分岐の有無は問わない。さらに、ポリマーの混合物が、IL-21結合体を生成するために使用され得る。
Claims (9)
- (i)成熟(mature)IL-21ポリペプチドまたはN末端のMetを備えた成熟(mature)IL-21ポリペプチド;および
(ii)少なくとも一つのSer, Tyr, LysまたはCysからなる1〜10個のアミノ酸の配列を介して前記IL-21ポリペプチドのN末端に連結された5 kDaまたは10 kDaの少なくとも二つのPEG分子
からなるヒトIL-21の誘導体であって、
少なくとも50 kDaの見かけのサイズを有するヒトIL-21の誘導体。 - 前記PEG分子が、Ser-hIL21に連結されている、請求項1に記載のヒトIL-21の誘導体。
- 請求項2に記載のヒトIL-21の誘導体を発現する単離されたDNA。
- 前記PEG分子が、5 kDaの重量を有する、請求項1に記載のヒトIL-21の誘導体。
- 前記PEG分子が、10 kDaの重量を有する、請求項1に記載のヒトIL-21の誘導体。
- 2〜8個のPEG分子が存在する、請求項1に記載のヒトIL-21の誘導体。
- 3〜6個のPEG分子が存在する、請求項6に記載のヒトIL-21の誘導体。
- 癌の治療のための薬物の製造のための、請求項1、2および4〜7の何れか一項に記載のヒトIL-21の誘導体の使用。
- 請求項1、2および4〜7の何れか一項に記載のヒトIL-21の誘導体を有効成分として含む、癌を治療するための薬学的組成物。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200301496 | 2003-10-10 | ||
US51089203P | 2003-10-14 | 2003-10-14 | |
DKPA200301529 | 2003-10-17 | ||
US51342203P | 2003-10-22 | 2003-10-22 | |
DKPA200400707 | 2004-05-04 | ||
US56956604P | 2004-05-10 | 2004-05-10 | |
PCT/DK2004/000686 WO2005035565A1 (en) | 2003-10-10 | 2004-10-08 | Il-21 derivatives |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011087574A Division JP2011184442A (ja) | 2003-10-10 | 2011-04-11 | Il−21の誘導体 |
JP2011198348A Division JP2012067100A (ja) | 2003-10-10 | 2011-09-12 | Il−21の誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007533298A JP2007533298A (ja) | 2007-11-22 |
JP2007533298A5 true JP2007533298A5 (ja) | 2010-10-07 |
Family
ID=42779898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006529654A Withdrawn JP2007533298A (ja) | 2003-10-10 | 2004-10-08 | Il−21の誘導体 |
Country Status (7)
Country | Link |
---|---|
EP (2) | EP2263684A1 (ja) |
JP (1) | JP2007533298A (ja) |
CN (2) | CN102516386A (ja) |
AT (1) | ATE481420T1 (ja) |
CA (1) | CA2542179A1 (ja) |
DE (1) | DE602004029173D1 (ja) |
WO (1) | WO2005035565A1 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2642214T3 (es) * | 2004-01-21 | 2017-11-15 | Novo Nordisk Health Care Ag | Conjugación de péptidos mediante transglutaminasa |
US8034326B2 (en) | 2005-04-18 | 2011-10-11 | Novo Nordisk A/S | IL-21 variants |
EP1890723A2 (en) * | 2005-06-06 | 2008-02-27 | Novo Nordisk A/S | Stabilised il-21 compositions |
BRPI0615351A2 (pt) | 2005-08-30 | 2011-05-17 | Novo Nordisk Healthcare Ag | formulações lìquidas de hormÈnio do crescimento peguilado |
EP1966232A1 (en) | 2005-12-23 | 2008-09-10 | Novo Nordisk A/S | Purification of proteins using preparative reverse phase chromatography (rpc) |
AU2007271150A1 (en) | 2006-07-07 | 2008-01-10 | Novo Nordisk Health Care Ag | New protein conjugates and methods for their preparation |
US8475784B2 (en) | 2006-10-26 | 2013-07-02 | Novo Nordisk A/S | IL-21 variants |
JP2010512769A (ja) | 2006-12-21 | 2010-04-30 | ノヴォ ノルディスク アクティーゼルスカブ | Il−21受容体との結合が変化したインターロイキン−21変異体 |
WO2015000585A1 (en) * | 2013-07-02 | 2015-01-08 | Walter Sebald | Muteins of cytokines of the gamma-chain receptor family conjugated to a non-protein group |
CN105198999A (zh) * | 2014-05-27 | 2015-12-30 | 上海生物制品研究所有限责任公司 | 一种融合蛋白、其制备方法及其应用 |
WO2020154187A1 (en) * | 2019-01-21 | 2020-07-30 | Sanofi | Therapeutic rna for advanced stage solid tumor cancers |
WO2024002170A1 (en) * | 2022-06-29 | 2024-01-04 | Beijing Neox Biotech Limited | Il-21 polypeptides and methods of use |
CN117645661A (zh) * | 2022-09-02 | 2024-03-05 | 北京志道生物科技有限公司 | 一种聚乙二醇修饰的il-21衍生物及其应用 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
GB8430252D0 (en) | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
DE3676670D1 (de) | 1985-06-26 | 1991-02-07 | Cetus Corp | Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung. |
GB8610551D0 (en) | 1986-04-30 | 1986-06-04 | Hoffmann La Roche | Polypeptide & protein derivatives |
GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
EP0325224B1 (en) | 1988-01-22 | 1996-07-31 | ZymoGenetics, Inc. | Methods of producing secreted receptor analogs |
US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
GB8824591D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
US4902502A (en) * | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
DE69034200T2 (de) | 1989-04-19 | 2006-05-24 | Enzon, Inc. | Verfahren zum Herstellen von modifizierten Polypeptiden die eine Polypeptid und ein Polyalkylenoxid enthalten |
EP0400472B1 (en) | 1989-05-27 | 1996-04-03 | Sumitomo Pharmaceuticals Company, Limited | Process for preparing polyethylene glycol derivatives and modified protein. |
US5219564A (en) | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
WO1992008790A1 (en) | 1990-11-14 | 1992-05-29 | Cargill, Incorporated | Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
WO1992016555A1 (en) | 1991-03-18 | 1992-10-01 | Enzon, Inc. | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
AU674525B2 (en) * | 1992-06-01 | 1997-01-02 | Magainin Pharmaceuticals, Inc. | Biologically active peptides having N-terminal substitutions |
ZA933926B (en) | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
AU5006993A (en) | 1992-08-21 | 1994-03-15 | Enzon, Inc. | Novel attachment of polyalkylene oxides to bio-effecting substances |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
NZ250375A (en) | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
US5298643A (en) | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
US5349001A (en) | 1993-01-19 | 1994-09-20 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
US5321095A (en) | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
IL104734A0 (en) | 1993-02-15 | 1993-06-10 | Univ Bar Ilan | Bioactive conjugates of cellulose with amino compounds |
WO1994028024A1 (en) | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
AU7113594A (en) | 1993-06-21 | 1995-01-17 | Enzon, Inc. | Site specific synthesis of conjugated peptides |
GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
EP0730470B1 (en) | 1993-11-10 | 2002-03-27 | Enzon, Inc. | Improved interferon polymer conjugates |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5473034A (en) | 1994-03-18 | 1995-12-05 | Hyogo Prefectural Government | Method for producing protein-synthetic polymer conjugate and said conjugate produced thereby |
US5629384A (en) | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
US5686110A (en) | 1994-06-02 | 1997-11-11 | Enzon, Inc. | Water soluble complex of an alkyl or olefinic end capped polyalkylene oxide and a water insoluble substance |
US5730990A (en) | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
EP0788375A2 (en) | 1994-11-09 | 1997-08-13 | Robin Ewart Offord | Functionalized polymers for site-specific attachment |
US5738846A (en) | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
WO1996040248A1 (en) * | 1995-06-07 | 1996-12-19 | Eukarion, Inc. | Transvacular and intracellular delivery of lipidized proteins |
WO1996040791A1 (en) | 1995-06-07 | 1996-12-19 | Novo Nordisk A/S | Modification of polypeptides |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
US5747639A (en) | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
JP4410852B2 (ja) | 1996-08-02 | 2010-02-03 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 単一の共有結合n末端水溶性ポリマーを有するポリペプチド |
JP2001508783A (ja) | 1997-01-29 | 2001-07-03 | ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー | Peg化法 |
WO1998049198A1 (en) | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
RO121474B1 (ro) | 1997-06-06 | 2007-06-29 | Kyowa Hakko Kogyo Co., Ltd. | Polipeptide modificate chimic |
BR9812267B1 (pt) * | 1997-07-14 | 2013-11-26 | Hormônio de crescimento recombinante. | |
US5981709A (en) | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
EP1075282B1 (en) | 1998-04-28 | 2005-06-15 | Applied Research Systems ARS Holding N.V. | Peg-lhrh analog conjugates |
US20010023070A1 (en) * | 1998-05-29 | 2001-09-20 | Reinhard Ebner | Interleukins-21 and 22 |
CA2329274A1 (en) * | 1998-05-29 | 1999-12-02 | Steven M. Ruben | Interleukin-21 |
MXPA01009074A (es) * | 1999-03-09 | 2002-03-27 | Zymogenetics Inc | Nuevo ligando zalfa11 de citocina. |
CA2452582C (en) * | 2001-07-11 | 2013-01-22 | Maxygen Holdings, Ltd. | G-csf conjugates |
CA2460916A1 (en) * | 2001-10-04 | 2003-04-10 | Laura Carter | Methods and compositions for modulating interleukin-21 receptor activity |
ATE444363T1 (de) * | 2001-11-05 | 2009-10-15 | Zymogenetics Inc | Il-21-antagonisten |
AU2003230834A1 (en) | 2002-04-09 | 2003-10-27 | Beth Israel Deaconess Medical Center, Inc. | Antagonists of il-21 and modulation of il-21-mediated t cell responses |
ES2381265T3 (es) * | 2002-06-07 | 2012-05-24 | Zymogenetics, Inc. | Uso de IL-21 y anticuerpo monoclonal para tratar cánceres sólidos |
MXPA05000655A (es) | 2002-07-15 | 2006-02-22 | Harvard College | Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th). |
JP4664684B2 (ja) | 2002-12-13 | 2011-04-06 | ザイモジェネティクス, インコーポレイテッド | 原核生物宿主におけるil−21の生産 |
EP1653996A2 (en) * | 2003-08-08 | 2006-05-10 | Novo Nordisk Health Care AG | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest |
-
2004
- 2004-10-08 EP EP10163849A patent/EP2263684A1/en not_active Withdrawn
- 2004-10-08 WO PCT/DK2004/000686 patent/WO2005035565A1/en active Application Filing
- 2004-10-08 AT AT04762905T patent/ATE481420T1/de active
- 2004-10-08 CN CN2011104026863A patent/CN102516386A/zh active Pending
- 2004-10-08 CA CA002542179A patent/CA2542179A1/en not_active Abandoned
- 2004-10-08 DE DE602004029173T patent/DE602004029173D1/de active Active
- 2004-10-08 JP JP2006529654A patent/JP2007533298A/ja not_active Withdrawn
- 2004-10-08 CN CN2004800296630A patent/CN1867581B/zh not_active Expired - Fee Related
- 2004-10-08 EP EP04762905A patent/EP1673387B1/en not_active Not-in-force
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ding et al. | Weak bond-based injectable and stimuli responsive hydrogels for biomedical applications | |
Zhang et al. | Manipulation of hydrogel assembly and growth factor delivery via the use of peptide–polysaccharide interactions | |
TWI685347B (zh) | 用於在活體中遞送RNAi觸發子至腫瘤細胞之聚結合物 | |
JP2007533298A5 (ja) | ||
US20200288709A1 (en) | Composition with high antimicrobial activity and low toxicity | |
Huang et al. | Marine-inspired molecular mimicry generates a drug-free, but immunogenic hydrogel adhesive protecting surgical anastomosis | |
Dong et al. | Injectable adhesive hydrogel through a microcapsule cross-link for periodontitis treatment | |
JP2012126750A5 (ja) | ||
JP2006513992A5 (ja) | ||
JPH02191629A (ja) | グラフト化ペプチド共重合体 | |
TW200812572A (en) | Polymer conjugate of taxane | |
WO2009152691A1 (zh) | 聚乙二醇修饰壳寡糖脂肪酸嫁接物及制备方法和应用 | |
Singh Dhillon et al. | Recent development in applications of important biopolymer chitosan in biomedicine, pharmaceuticals and personal care products | |
Cui et al. | Molecular engineering of antimicrobial peptide (AMP)–polymer conjugates | |
WO2010128672A1 (ja) | 遺伝子組み換えゼラチンを含む血管新生誘導剤 | |
JP2003321500A (ja) | 新規なポリペプチドおよびその製造方法 | |
Peng et al. | Scarless wound closure by a mussel-inspired poly (amidoamine) tissue adhesive with tunable degradability | |
Asai et al. | In situ depot formation of anti-HIV fusion-inhibitor peptide in recombinant protein polymer hydrogel | |
Gao et al. | Immune enhancement of N-2-Hydroxypropyl trimethyl ammonium chloride chitosan/carboxymethyl chitosan nanoparticles vaccine | |
KR20210052473A (ko) | 면역조정 특성을 갖는 펩티드 | |
US20210023121A1 (en) | Thrombin-responsive hydrogels and devices for auto-anticoagulant regulation | |
IL296230A (en) | preparations to stop bleeding | |
JP3862361B2 (ja) | 医療用手当材およびそれに用いる新規なペプチド | |
Li et al. | Enzyme-Triggered Polyelectrolyte Complex for Responsive Delivery of α-Helical Polypeptides to Optimize Antibacterial Therapy | |
KR20210031478A (ko) | 고분자 화합물 및 이를 이용한 세포내 화합물 도입 촉진제 |